1
|
Methaapanon R, Geyer SM, Hagglund C, Pianetta PA, Bent SF. Portable atomic layer deposition reactor for in situ synchrotron photoemission studies. Rev Sci Instrum 2013; 84:015104. [PMID: 23387692 DOI: 10.1063/1.4773230] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
We report the design of a portable atomic layer deposition (ALD) reactor that can be integrated into synchrotron facilities for in situ synchrotron photoemission studies. The design allows for universal installation of the system onto different beam line end stations. The ALD reactor operates as a fully functional, low vacuum deposition system under the conditions of a typical ALD reactor while allowing the samples to be analyzed in an ultrahigh vacuum (UHV) chamber through a quick transfer without vacuum break. This system not only minimizes the exposure of the UHV chamber to the ALD reactants, but it also eliminates the necessity of a beam alignment step after installation. The system has been successfully installed at the synchrotron and tested in the mechanistic studies of platinum ALD following individual half reaction cycles.
Collapse
Affiliation(s)
- R Methaapanon
- Department of Chemical Engineering, Stanford University, Stanford, California 94305, USA
| | | | | | | | | |
Collapse
|
2
|
Moley JF, Adkins D, Bible KC, Traynor AM, Molina JR, Colon-Otero G, Pluard TJ, Shah MH, Suresh R, Erlichman C, Ivy SP, Suman V, Geyer SM, Fracasso PM, Cohen MS, Tang H, Fialkowski E, Traugott A, Smallridge RC. 17-allylaminogeldanamycin in advanced medullary and differentiated thyroid carcinoma. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.5582] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
3
|
Viswanathan S, Wesolowski R, Layman RM, Alejandra G, Miller B, Chalmers JJ, Bejastani S, Zhao W, Pierluigu G, Cotrill J, Phelps MA, Schaaf LJ, Geyer SM, Hall N, Knopp MV, Shapiro CL, Villalona-Calero MA, Chen A, Grever MR, Ramaswamy B. A phase I dose-escalation study of ABT-888 (veliparib) in combination with carboplatin in HER2-negative metastatic breast cancer (MBC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.tps106] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
4
|
Mesa RA, Camoriano JK, Geyer SM, Wu W, Kaufmann SH, Rivera CE, Erlichman C, Wright J, Pardanani A, Lasho T, Finke C, Li CY, Tefferi A. A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia. Leukemia 2007; 21:1964-70. [PMID: 17581608 DOI: 10.1038/sj.leu.2404816] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Patients with primary myelofibrosis (PMF) or post-polycythemia vera or post-essential thrombocythemia myelofibrosis (post-PV/ET MF) have limited therapeutic options. The farnesyltransferase-inhibitor tipifarnib inhibits in vitro proliferation of myeloid progenitors from such patients. In the current phase II clinical trial, single-agent oral tipifarnib (300 mg twice daily x 21 of 28 days) was given to 34 symptomatic patients with either PMF (n=28) or post-PV/ET MF (n=6). Median time to discontinuation of protocol therapy was 4.6 months; reasons for early termination (n=19; 56%) included disease progression (21%) and adverse drug effects (18%). Toxicities (>/=grade 3) included myelosuppression (n=16), neuropathy (n=2), fatigue (n=1), rash (n=1) and hyponatremia (n=1). Response rate was 33% for hepatosplenomegaly and 38% for transfusion-requiring anemia. No favorable changes occurred in bone marrow fibrosis, angiogenesis or cytogenetic status. Pre- and post-treatment patient sample analysis for in vitro myeloid colony growth revealed substantial reduction in the latter. Clinical response did not correlate with either degree of colony growth, measurable decrease in quantitative JAK2(V617F) levels or tipifarnib IC(50) values (median 11.8 nM) seen in pretreatment samples. The current study indicates both in vitro and in vivo tipifarnib activity in PMF and post-PV/ET MF.
Collapse
Affiliation(s)
- R A Mesa
- Division of Hematology, Rochester, MN, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Lust JA, Lacy MQ, Zeldenrust SR, Dispenzieri A, Gertz MA, Greipp PR, Witzig TE, Kumar S, Geyer SM, Donovan KA. Prevention of active multiple myeloma (MM) using IL-1 receptor antagonist (IL-1ra) and low-dose dexamethasone (Dex) and monitoring the high sensitivity C-reactive protein (hsCRP). J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.8105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8105 Background: IL-6 is the central myeloma growth factor and we have shown that abnormal production of IL-1beta in the myeloma microenvironment stimulates the generation of paracrine IL-6. A Phase II trial was completed using IL-1ra, which inhibits paracrine IL-6 production, and low dose Dexamethasone (Dex), which decreases IL-1 levels through myeloma cell apoptosis, in patients with smoldering/indolent MM (SMM/IMM). These patients are at the greatest risk for progression to active MM and most likely to benefit from anti- cytokine therapy. Methods: Patients that had ≥ 10% bone marrow plasma cells and/or an IgG or IgA M-spike ≥ 3 g/dL and did not require immediate chemotherapy were eligible. A total of 47 patients received 100 mg of IL-1ra SQ qd for 6 months unless clinical progression occurred. Responding patients were allowed to continue on therapy with IL-1ra alone. Low dose Dex (20 mg qweek) was added after 6 months of IL-1ra in non-responding patients. The primary endpoint was progression-free survival (PFS). Results: The 47 patients were at high risk for progression to active MM with 98% having ≥ 10% plasma cells, 89% generating IL-1 levels consistent with myeloma (≥ 1.0), and 32% having bone lesions. All 47 patients received IL-1ra initially and 25/47 subsequently received IL-1Ra/Dex. For the group of 47 patients, the median overall progression-free survival was 37.5 months. Three patients achieved a minor response (MR) to Anakinra alone; 5 pts achieved a PR and 4 patients an MR after addition of Dex. Seven patients had a decrease in the plasma cell labeling index (PCLI; a marker of myeloma cell growth) on Anakinra alone which paralleled a decrease in the high sensitivity CRP (a marker of serum IL-6 levels). The median PFS for patients without (n=12) and with (n=35) a ≥ 15% decrease in their baseline hsCRP was 6 months and > 3 yrs, respectively (p=0.002). Conclusions: In SMM/IMM patients at high risk for progression to active myeloma, treatment with IL-1 inhibitors (IL-1ra ± Dex) results in an increased PFS in patients that demonstrate a ≥15% reduction in the baseline CRP compared to those that do not respond. No significant financial relationships to disclose.
Collapse
|
6
|
Johnston PB, Ansell SM, Colgan JP, Habermann TM, Inwards DJ, Markovic SN, Micallef IN, Porrata LF, LaPlant BR, Geyer SM, Witzig TE. Phase II trial of the oral mTOR inhibitor everolimus (RAD001) for patients with relapsed or refractory lymphoma. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.8055] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8055 Background: mTOR inhibition with intravenous temsirolimus (Wyeth Pharmaceuticals) has been associated with responses in mantle cell lymphoma (J Clin Oncol 23;5347, 2005) as well as other lymphomas (Blood 108 (11) 2483; 2006). This phase II study tested the oral mTOR inhibitor everolimus (RAD001, Novartis Pharmaceuticals) in three simultaneous two-stage phase II lymphoma studies - aggressive (group 1), indolent (group 2), or uncommon (group 3). The goals were to learn the toxicity profile and to assess the anti-tumor response. Planned interim analysis for groups 1 and 3 have been completed and are the subject of this report. Methods: Patients (pts) received 10 mg PO daily for each 28 day cycle (up to 12) and restaged after 2, 6, and 12 cycles. The primary endpoint is the confirmed response rate, including CR, CRu or PR. 12 pts were enrolled in stage 1 of each study. At least 1 success in 12 is required to proceed to stage 2, to a total of 37 pts. Overall, the treatment will be considered promising if 4 or more successes are observed in all 37 pts in each group. Results: The median age of the 12 pts in group 1 was 68.5 yrs (range: 53–80), with a median of 3 (range, 1–15) prior therapies. Four pts had a prior stem cell transplant (SCT). Pts completed a median of 7 (range, 1–12) cycles of therapy. 6 confirmed responses have been achieved (1 CR, 5 PR), meeting the overall criteria for promising results in this study. Common grade 3 adverse events (AEs) include thrombocytopenia (3 pts) and anemia (2 pts). For group 3, the median age was 49 yrs (range, 27–78), with a median of 7 (range, 1–13) prior therapies and 6 pts had a prior SCT. Pts have completed a median of 6.5 cycles (range, 1–11). 5 confirmed responses have been achieved (5 PR), meeting the criteria for this regimen to be considered promising. Of these 5 patients, 3 had HD, 1 T-cell NHL, and 1 had macroglobulinemia. Common grade 3 AEs include anemia (3 pts) and thrombocytopenia (2 pts). No grade 4 AEs were reported. Conclusions: Oral everolimus has activity in a spectrum of lymphomas with acceptable toxicity. The responses observed in both group 1 and group 3 met the criteria to continue accrual. These results provide the rationale for additional studies with this novel class of agents and to integrate mTOR inhibitors into salvage treatment regimens. No significant financial relationships to disclose.
Collapse
|
7
|
Kurtz DM, Tschetter LK, Allred JB, Geyer SM, Kurtin PJ, Putnam WD, Rowland KM, Wiesenfeld M, Soori GS, Tenglin RC, Bernath AM, Witzig TE. SUBCUTANEOUS INTERLEUKIN-4 FOR RELAPSED NON-HODGKINʼS LYMPHOMA: A PHASE II TRIAL IN THE NORTH CENTRAL CANCER TREATMENT GROUP, NCCTG 91-78-51. J Investig Med 2007. [DOI: 10.1097/00042871-200703010-00088] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
8
|
Kurtz DM, Tschetter LK, Allred JB, Geyer SM, Kurtin PJ, Putnam WD, Rowland KM, Wiesenfeld M, Soori GS, Tenglin RC, Bernath AM, Witzig TE. 81 SUBCUTANEOUS INTERLEUKIN-4 FOR RELAPSED NON-HODGKIN'S LYMPHOMA: A PHASE II TRIAL IN THE NORTH CENTRAL CANCER TREATMENT GROUP, NCCTG 91-78-51. J Investig Med 2007. [DOI: 10.1136/jim-55-02-81] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
9
|
Ansell SM, Geyer SM, Kurtin PJ, Inwards DJ, Kaufmann SH, Flynn PJ, Morton RF, Luyun RF, Dakhil SR, Gross H, Witzig TE. Anti-tumor activity of mTOR inhibitor temsirolimus for relapsed mantle cell lymphoma: A phase II trial in the North Central Cancer Treatment Group. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.7532] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7532 Background: Mantle Cell Lymphoma (MCL) is characterized by t(11;14) resulting in over expression of cyclin D1, a member of the phosphatidylinosital 3-kinase (PI3K) pathway. Temsirolimus is a novel inhibitor of the mammalian target of rapamycin (mTOR) kinase. Previous studies with weekly temsirolimus at a dose of 250mg demonstrated a 38% overall response rate in 35 patients (JCO 23 (23); 5347–56, 2005). Thrombocytopenia was frequently observed and was dose limiting. The current study tested whether low-doses (25mg) of temsirolimus could produce a similar overall response rate (ORR) with less toxicity. Methods: Eligible patients had biopsy proven cyclin D1 positive MCL and had relapsed or were refractory to therapy. Patients received temsirolimus 25mg IV weekly as a single agent. Patients were restaged after 1 cycle (4 doses), after 3 cycles, and every 3 cycles thereafter. Patients with a tumor response after 6 cycles were eligible to continue drug for a total of 12 or 2 cycles after complete remission (CR) and then were observed without maintenance. The goal was to achieve an ORR of at least 20%. Results: Twenty-nine patients were enrolled between March and August 2005. Twenty-two patients have completed therapy. One patient with a major protocol violation on cycle-1 and one ineligible patient were excluded, leaving 27 evaluable patients. The ORR was 41% (11/27), with 1 CR and 10 PRs. Early evaluation of TTP showed a median of 5.5 months (95% CI: 3.3–7.7) and the duration of response for the 11 responders was 6.2 months (95% CI: 3.6 to not yet reached). These results compare favorably with the 6.5 months and 6.9 months, respectively, found in previous trials that used 250 mg. The median dose delivered per month was 80 mg (range, 10–100 mg). Sixteen (59%) of patients required a dose reduction. The median time on treatment was 4.4 months (95% CI, 3.3–7.7). The incidence of grade 3 and 4 thrombocytopenia was 12% and 0%, respectively. One patient experienced grade 5 infection without neutropenia, which was considered unrelated to CCI-779. Conclusions: Single agent CCI-779 at a dose of 25mg has anti-tumor activity in relapsed MCL similar to the 250 mg dose. This study indicates that combinations of temsirolimus with other agents should be feasible. [Table: see text]
Collapse
Affiliation(s)
- S. M. Ansell
- Mayo Clinic, Rochester, MN; Metro-Minnesota Community Clinical Oncology Program, St. Louis Park, MN; Iowa Oncology Research Association CCOP, Des Moines, IA; Carle Cancer Center, Urbana, IL; Wichita Community Clinical Oncology Program, Wichita, KS; Hematology and Oncology of Dayton, Inc, Dayton, OH
| | - S. M. Geyer
- Mayo Clinic, Rochester, MN; Metro-Minnesota Community Clinical Oncology Program, St. Louis Park, MN; Iowa Oncology Research Association CCOP, Des Moines, IA; Carle Cancer Center, Urbana, IL; Wichita Community Clinical Oncology Program, Wichita, KS; Hematology and Oncology of Dayton, Inc, Dayton, OH
| | - P. J. Kurtin
- Mayo Clinic, Rochester, MN; Metro-Minnesota Community Clinical Oncology Program, St. Louis Park, MN; Iowa Oncology Research Association CCOP, Des Moines, IA; Carle Cancer Center, Urbana, IL; Wichita Community Clinical Oncology Program, Wichita, KS; Hematology and Oncology of Dayton, Inc, Dayton, OH
| | - D. J. Inwards
- Mayo Clinic, Rochester, MN; Metro-Minnesota Community Clinical Oncology Program, St. Louis Park, MN; Iowa Oncology Research Association CCOP, Des Moines, IA; Carle Cancer Center, Urbana, IL; Wichita Community Clinical Oncology Program, Wichita, KS; Hematology and Oncology of Dayton, Inc, Dayton, OH
| | - S. H. Kaufmann
- Mayo Clinic, Rochester, MN; Metro-Minnesota Community Clinical Oncology Program, St. Louis Park, MN; Iowa Oncology Research Association CCOP, Des Moines, IA; Carle Cancer Center, Urbana, IL; Wichita Community Clinical Oncology Program, Wichita, KS; Hematology and Oncology of Dayton, Inc, Dayton, OH
| | - P. J. Flynn
- Mayo Clinic, Rochester, MN; Metro-Minnesota Community Clinical Oncology Program, St. Louis Park, MN; Iowa Oncology Research Association CCOP, Des Moines, IA; Carle Cancer Center, Urbana, IL; Wichita Community Clinical Oncology Program, Wichita, KS; Hematology and Oncology of Dayton, Inc, Dayton, OH
| | - R. F. Morton
- Mayo Clinic, Rochester, MN; Metro-Minnesota Community Clinical Oncology Program, St. Louis Park, MN; Iowa Oncology Research Association CCOP, Des Moines, IA; Carle Cancer Center, Urbana, IL; Wichita Community Clinical Oncology Program, Wichita, KS; Hematology and Oncology of Dayton, Inc, Dayton, OH
| | - R. F. Luyun
- Mayo Clinic, Rochester, MN; Metro-Minnesota Community Clinical Oncology Program, St. Louis Park, MN; Iowa Oncology Research Association CCOP, Des Moines, IA; Carle Cancer Center, Urbana, IL; Wichita Community Clinical Oncology Program, Wichita, KS; Hematology and Oncology of Dayton, Inc, Dayton, OH
| | - S. R. Dakhil
- Mayo Clinic, Rochester, MN; Metro-Minnesota Community Clinical Oncology Program, St. Louis Park, MN; Iowa Oncology Research Association CCOP, Des Moines, IA; Carle Cancer Center, Urbana, IL; Wichita Community Clinical Oncology Program, Wichita, KS; Hematology and Oncology of Dayton, Inc, Dayton, OH
| | - H. Gross
- Mayo Clinic, Rochester, MN; Metro-Minnesota Community Clinical Oncology Program, St. Louis Park, MN; Iowa Oncology Research Association CCOP, Des Moines, IA; Carle Cancer Center, Urbana, IL; Wichita Community Clinical Oncology Program, Wichita, KS; Hematology and Oncology of Dayton, Inc, Dayton, OH
| | - T. E. Witzig
- Mayo Clinic, Rochester, MN; Metro-Minnesota Community Clinical Oncology Program, St. Louis Park, MN; Iowa Oncology Research Association CCOP, Des Moines, IA; Carle Cancer Center, Urbana, IL; Wichita Community Clinical Oncology Program, Wichita, KS; Hematology and Oncology of Dayton, Inc, Dayton, OH
| |
Collapse
|
10
|
Witzig TE, Geyer SM, Kurtin PJ, Colgan JP, Inwards DJ, Micallef IN, Michalak JC, Salim M, Nikcevich DA, Dakhil SR, Fitch TR. Salvage chemotherapy with rituximab DHAP (RDHAP) for relapsed non-hodgkin lymphoma (NHL): A phase II trial in the North Central Cancer Treatment Group. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.7574] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7574 Background: Patients (pts) with relapsed aggressive NHL are usually treated with intensive platinum-based chemotherapy regimens prior to stem cell transplant (SCT). This study was designed to learn the toxicity and efficacy of adding 4 doses of rituximab to the standard DHAP salvage chemotherapy regimen. Methods: Eligible pts had biopsy-proven relapsed CD20+ NHL and were eligible for platinum-based chemotherapy. Pts were treated with rituximab 375 mg/m2 d1,8,15, and 22 as well as cis-platinum 100 mg/m2 d3, cytosine arabinoside 2 g/m2 IV q 12 hours x two doses d4, dexamethasone 40 mg PO/IV d3–6, and G-CSF d5–14. Pts were restaged after 1 and 2 cycles; responding pts could proceed to SCT or further cycles of DHAP at MD discretion. There was no provision for rituximab maintenance. The goal was to achieve an overall response rate (ORR) of ≥ 75%. Results: Fifty-eight pts were enrolled between 10/29/00 and 6/20/03. The median age was 63 years (range, 43–83). One pt was ineligible because the tumor was CD20-. All 57 eligible pts completed one cycle; 48 pts completed 2 cycles. The ORR was 70% (40/57) with 16 (28%) CR/CRu and 24 (42%) PR. For all 57 pts, the median TTP was 13.1 months (mos) (95% CI: 7.3–18.2) and the median OS 30.5 mos (95% CI: 17.8–52.5). Seventeen pts (30%) proceeded to SCT. The median duration of response (DR), time to progression (TTP) and overall survival (OS) for the SCT pts were 41.6, 42.3, and 43.6 mos, respectively. The median DR, TTP, and OS for the 25 pts who responded to RDHAP but did not proceed to SCT were 12.4, 13.1, and 38.8 mos, respectively. The incidence of grade 3 and 4 thrombocytopenia was 53% and 39%, respectively. The incidence of grade 3 and 4 neutropenia was 11% and 68%, respectively. Six pts (11%) had nephrotoxicity–five grade 3 and two grade 4 (one pt had both) and one pt required dialysis. Conclusions: The addition of rituximab to standard DHAP is safe with similar toxicity profile to DHAP alone. Despite a high ORR, the CR rate and the % pts proceeding to SCT in this cooperative group setting remain low. New agents are needed that can be added to these regimens to increase the effectiveness and reduce toxicity to allow more pts to proceed to SCT. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- T. E. Witzig
- Mayo Clinic, Rochester, MN; Siouxland Regional Cancer Center, Sioux City, IA; Allan Blair Cancer Center, Regina, SK, Canada; Duluth Clinic, Duluth, MN; Wichita Community Clinical Oncology Program, Wichita, KS; Mayo Clinic, Scottsdale, AZ
| | - S. M. Geyer
- Mayo Clinic, Rochester, MN; Siouxland Regional Cancer Center, Sioux City, IA; Allan Blair Cancer Center, Regina, SK, Canada; Duluth Clinic, Duluth, MN; Wichita Community Clinical Oncology Program, Wichita, KS; Mayo Clinic, Scottsdale, AZ
| | - P. J. Kurtin
- Mayo Clinic, Rochester, MN; Siouxland Regional Cancer Center, Sioux City, IA; Allan Blair Cancer Center, Regina, SK, Canada; Duluth Clinic, Duluth, MN; Wichita Community Clinical Oncology Program, Wichita, KS; Mayo Clinic, Scottsdale, AZ
| | - J. P. Colgan
- Mayo Clinic, Rochester, MN; Siouxland Regional Cancer Center, Sioux City, IA; Allan Blair Cancer Center, Regina, SK, Canada; Duluth Clinic, Duluth, MN; Wichita Community Clinical Oncology Program, Wichita, KS; Mayo Clinic, Scottsdale, AZ
| | - D. J. Inwards
- Mayo Clinic, Rochester, MN; Siouxland Regional Cancer Center, Sioux City, IA; Allan Blair Cancer Center, Regina, SK, Canada; Duluth Clinic, Duluth, MN; Wichita Community Clinical Oncology Program, Wichita, KS; Mayo Clinic, Scottsdale, AZ
| | - I. N. Micallef
- Mayo Clinic, Rochester, MN; Siouxland Regional Cancer Center, Sioux City, IA; Allan Blair Cancer Center, Regina, SK, Canada; Duluth Clinic, Duluth, MN; Wichita Community Clinical Oncology Program, Wichita, KS; Mayo Clinic, Scottsdale, AZ
| | - J. C. Michalak
- Mayo Clinic, Rochester, MN; Siouxland Regional Cancer Center, Sioux City, IA; Allan Blair Cancer Center, Regina, SK, Canada; Duluth Clinic, Duluth, MN; Wichita Community Clinical Oncology Program, Wichita, KS; Mayo Clinic, Scottsdale, AZ
| | - M. Salim
- Mayo Clinic, Rochester, MN; Siouxland Regional Cancer Center, Sioux City, IA; Allan Blair Cancer Center, Regina, SK, Canada; Duluth Clinic, Duluth, MN; Wichita Community Clinical Oncology Program, Wichita, KS; Mayo Clinic, Scottsdale, AZ
| | - D. A. Nikcevich
- Mayo Clinic, Rochester, MN; Siouxland Regional Cancer Center, Sioux City, IA; Allan Blair Cancer Center, Regina, SK, Canada; Duluth Clinic, Duluth, MN; Wichita Community Clinical Oncology Program, Wichita, KS; Mayo Clinic, Scottsdale, AZ
| | - S. R. Dakhil
- Mayo Clinic, Rochester, MN; Siouxland Regional Cancer Center, Sioux City, IA; Allan Blair Cancer Center, Regina, SK, Canada; Duluth Clinic, Duluth, MN; Wichita Community Clinical Oncology Program, Wichita, KS; Mayo Clinic, Scottsdale, AZ
| | - T. R. Fitch
- Mayo Clinic, Rochester, MN; Siouxland Regional Cancer Center, Sioux City, IA; Allan Blair Cancer Center, Regina, SK, Canada; Duluth Clinic, Duluth, MN; Wichita Community Clinical Oncology Program, Wichita, KS; Mayo Clinic, Scottsdale, AZ
| |
Collapse
|
11
|
Witzig TE, Ansell SM, Geyer SM, Kurtin PJ, Rowland KM, Flynn PJ, Morton RF, Dakhil SR, Gross HM, Maurer MJ, Kaufmann SH. Anti-tumor activity of low-dose single agent CCI-779 for relapsed mantle celllLymphoma: A phase II trial in the North Central Cancer Treatment Group. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.6504] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- T. E. Witzig
- Mayo Clinic, Rochester, MN; Carle Cancer Ctr, Urbana, IL; Metro-Minnesota Community Clin Oncology, St. Louis Park, MN; Medcl Oncology & Hematology Assoc, Des Moines, IA; Wichita Community Clin Oncology Program, Wichita, KS; Hematology & Oncology of Dayton, Inc, Dayton, OH
| | - S. M. Ansell
- Mayo Clinic, Rochester, MN; Carle Cancer Ctr, Urbana, IL; Metro-Minnesota Community Clin Oncology, St. Louis Park, MN; Medcl Oncology & Hematology Assoc, Des Moines, IA; Wichita Community Clin Oncology Program, Wichita, KS; Hematology & Oncology of Dayton, Inc, Dayton, OH
| | - S. M. Geyer
- Mayo Clinic, Rochester, MN; Carle Cancer Ctr, Urbana, IL; Metro-Minnesota Community Clin Oncology, St. Louis Park, MN; Medcl Oncology & Hematology Assoc, Des Moines, IA; Wichita Community Clin Oncology Program, Wichita, KS; Hematology & Oncology of Dayton, Inc, Dayton, OH
| | - P. J. Kurtin
- Mayo Clinic, Rochester, MN; Carle Cancer Ctr, Urbana, IL; Metro-Minnesota Community Clin Oncology, St. Louis Park, MN; Medcl Oncology & Hematology Assoc, Des Moines, IA; Wichita Community Clin Oncology Program, Wichita, KS; Hematology & Oncology of Dayton, Inc, Dayton, OH
| | - K. M. Rowland
- Mayo Clinic, Rochester, MN; Carle Cancer Ctr, Urbana, IL; Metro-Minnesota Community Clin Oncology, St. Louis Park, MN; Medcl Oncology & Hematology Assoc, Des Moines, IA; Wichita Community Clin Oncology Program, Wichita, KS; Hematology & Oncology of Dayton, Inc, Dayton, OH
| | - P. J. Flynn
- Mayo Clinic, Rochester, MN; Carle Cancer Ctr, Urbana, IL; Metro-Minnesota Community Clin Oncology, St. Louis Park, MN; Medcl Oncology & Hematology Assoc, Des Moines, IA; Wichita Community Clin Oncology Program, Wichita, KS; Hematology & Oncology of Dayton, Inc, Dayton, OH
| | - R. F. Morton
- Mayo Clinic, Rochester, MN; Carle Cancer Ctr, Urbana, IL; Metro-Minnesota Community Clin Oncology, St. Louis Park, MN; Medcl Oncology & Hematology Assoc, Des Moines, IA; Wichita Community Clin Oncology Program, Wichita, KS; Hematology & Oncology of Dayton, Inc, Dayton, OH
| | - S. R. Dakhil
- Mayo Clinic, Rochester, MN; Carle Cancer Ctr, Urbana, IL; Metro-Minnesota Community Clin Oncology, St. Louis Park, MN; Medcl Oncology & Hematology Assoc, Des Moines, IA; Wichita Community Clin Oncology Program, Wichita, KS; Hematology & Oncology of Dayton, Inc, Dayton, OH
| | - H. M. Gross
- Mayo Clinic, Rochester, MN; Carle Cancer Ctr, Urbana, IL; Metro-Minnesota Community Clin Oncology, St. Louis Park, MN; Medcl Oncology & Hematology Assoc, Des Moines, IA; Wichita Community Clin Oncology Program, Wichita, KS; Hematology & Oncology of Dayton, Inc, Dayton, OH
| | - M. J. Maurer
- Mayo Clinic, Rochester, MN; Carle Cancer Ctr, Urbana, IL; Metro-Minnesota Community Clin Oncology, St. Louis Park, MN; Medcl Oncology & Hematology Assoc, Des Moines, IA; Wichita Community Clin Oncology Program, Wichita, KS; Hematology & Oncology of Dayton, Inc, Dayton, OH
| | - S. H. Kaufmann
- Mayo Clinic, Rochester, MN; Carle Cancer Ctr, Urbana, IL; Metro-Minnesota Community Clin Oncology, St. Louis Park, MN; Medcl Oncology & Hematology Assoc, Des Moines, IA; Wichita Community Clin Oncology Program, Wichita, KS; Hematology & Oncology of Dayton, Inc, Dayton, OH
| |
Collapse
|
12
|
Geyer SM, Markovic SM, Fitch TR, Albertini MR, Maples WJ, Fracasso PM, Erlichman C. Phase 2 study of PS-341 (bortezomib) in the treatment of metastatic malignant melanoma (MMM). J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.7526] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- S. M. Geyer
- Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AZ; University of Wisconsin, Madison, WI; Mayo Clinic, Jacksonville, FL; Washington University, St. Louis, MO
| | - S. M. Markovic
- Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AZ; University of Wisconsin, Madison, WI; Mayo Clinic, Jacksonville, FL; Washington University, St. Louis, MO
| | - T. R. Fitch
- Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AZ; University of Wisconsin, Madison, WI; Mayo Clinic, Jacksonville, FL; Washington University, St. Louis, MO
| | - M. R. Albertini
- Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AZ; University of Wisconsin, Madison, WI; Mayo Clinic, Jacksonville, FL; Washington University, St. Louis, MO
| | - W. J. Maples
- Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AZ; University of Wisconsin, Madison, WI; Mayo Clinic, Jacksonville, FL; Washington University, St. Louis, MO
| | - P. M. Fracasso
- Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AZ; University of Wisconsin, Madison, WI; Mayo Clinic, Jacksonville, FL; Washington University, St. Louis, MO
| | - C. Erlichman
- Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AZ; University of Wisconsin, Madison, WI; Mayo Clinic, Jacksonville, FL; Washington University, St. Louis, MO
| |
Collapse
|
13
|
Ansell SM, Geyer SM, Witzig TE, Jelinek DF, Kurtin PJ, Micallef INM, Stella P, Etzell P, Erlichman C, Novak AJ. NCCTG trial of concomitant or sequential IL-12 in combination with rituximab in previously treated non-Hodgkin lymphoma patients. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.6591] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
14
|
Porrata LF, Gertz MA, Geyer SM, Litzow MR, Gastineau DA, Moore SB, Pineda AA, Bundy KL, Padley DJ, Persky D, Lacy MQ, Dispenzieri A, Snow DS, Markovic SN. The dose of infused lymphocytes in the autograft directly correlates with clinical outcome after autologous peripheral blood hematopoietic stem cell transplantation in multiple myeloma. Leukemia 2004; 18:1085-92. [PMID: 15042106 DOI: 10.1038/sj.leu.2403341] [Citation(s) in RCA: 79] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Absolute lymphocyte count at day 15 (ALC-15) after autologous peripheral blood hematopoietic stem cell transplantation (APHSCT) is an independent prognostic factor for survival in multiple myeloma (MM); however, factors affecting ALC-15 in MM remain unknown. We hypothesized that the dose of infused peripheral blood autograft lymphocytes (autograft absolute lymphocyte count: A-ALC) impacts ALC-15 recovery. Between 1989 and 2001, 267 consecutive MM patients underwent APHSCT. We set out to determine the correlation between A-ALC and ALC-15 and the utility of A-ALC as a marker for ALC-15 recovery. A-ALC was found to be both a strong predictor for area under curve (AUC=0.93; P=0.0001) and strongly correlated with (r(s)=0.83; P=0.0001) ALC-15 recovery. Higher infused A-ALC was significantly correlated with an ALC-15>/=500/microl. In addition, median post-transplant overall survival (OS) and time to progression (TTP) were longer in patients who received an A-ALC>/=0.5 x 10(9) lymphocytes/kg versus A-ALC <0.5 x 10(9) lymphocytes/kg (58 vs 30 months, P=0.00022; 22 vs 15 months, P<0.00012, respectively). Multivariate analysis demonstrated A-ALC as an independent prognostic indicator for OS and TTP. These results indicate that an infused dose of autograft lymphocytes significantly impacts clinical outcome post-APHSCT in MM.
Collapse
Affiliation(s)
- L F Porrata
- Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Howe R, Micallef INM, Inwards DJ, Ansell SM, Dewald GW, Dispenzieri A, Gastineau DA, Gertz MA, Geyer SM, Hanson CA, Lacy MQ, Tefferi A, Litzow MR. Secondary myelodysplastic syndrome and acute myelogenous leukemia are significant complications following autologous stem cell transplantation for lymphoma. Bone Marrow Transplant 2003; 32:317-24. [PMID: 12858205 DOI: 10.1038/sj.bmt.1704124] [Citation(s) in RCA: 48] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Secondary myelodysplastic syndrome (sMDS) and acute myelogenous leukemia (AML) have been recognized with increasing frequency following autologous stem cell transplantation (ASCT). A retrospective analysis of 230 consecutive patients with Hodgkin's lymphoma (HL, 64) and non-Hodgkin's lymphoma (NHL, 166) who underwent ASCT was conducted to assess the incidence and risk factors for the development of sMDS/AML. At a median follow up of 41 months (range 0.1-177 months), 10 of 230 patients (4.3%) developed sMDS/AML. The 5-year-actuarial incidence of sMDS/AML was 13.1% and 5-year cumulative incidence by competing risk analysis was 4.2%. The median time to development of sMDS/AML was 39.9 months from the time of ASCT (range 12.1-62.0 months). Complex karyotypes at diagnosis of sMDS/AML included structural anomalies and/or loss of chromosome 5 (eight patients), 7 (five patients), 17 (two patients) and 20 (two patients). All patients subsequently died, at a median of 6.8 months (range 0-39.9) from diagnosis of sMDS/AML. Fluorescent in situ hybridization (FISH) analysis for -5/5q- and -7/7q- were normal in all six patients whose pre-ASCT bone marrow was available for testing. Five of the six had samples available for testing at diagnosis of sMDS/AML and all had abnormal FISH results. By univariate statistical analysis, male gender (P=0.01), prior alkylating agents (mechlorethamine for HL, P=0.001 and cyclophosphamide for NHL, P=0.05) and the number of prior treatment regimens (P=0.04) were significantly associated with the development of sMDS/AML. Given the relatively low incidence rate of sMDS/AML, these analyses are primarily exploratory in nature but provide some insight into relevant risk factors and illustrate the risk of developing sMDS/AML after myeloablative conditioning and ASCT for lymphoma.
Collapse
Affiliation(s)
- R Howe
- Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester MN 55905, USA
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Rajkumar SV, Gertz MA, Lacy MQ, Dispenzieri A, Fonseca R, Geyer SM, Iturria N, Kumar S, Lust JA, Kyle RA, Greipp PR, Witzig TE. Thalidomide as initial therapy for early-stage myeloma. Leukemia 2003; 17:775-9. [PMID: 12682636 DOI: 10.1038/sj.leu.2402866] [Citation(s) in RCA: 191] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Patients with early-stage myeloma are typically observed without therapy until symptomatic disease occurs. However, they are at high risk of progression to symptomatic myeloma, with a median time to progression of approximately 1-2 years. We report the final results of a phase II trial of thalidomide as initial therapy for early-stage multiple myeloma in an attempt to delay progression to symptomatic disease. In total, 31 patients with smoldering or indolent multiple myeloma were studied at the Mayo Clinic. Two patients were deemed ineligible because they were found to have received prior therapy for myeloma, and were excluded from analyses except for toxicity. Thalidomide was initiated at a starting dose of 200 mg/day. Patients were followed-up monthly for the first 6 months and every 3 months thereafter. Of the 29 eligible patients, 10 (34%) had a partial response to therapy with at least 50% or greater reduction in serum and urine monoclonal (M) protein. When minor responses (25-49% decrease in M protein) were included, the response rate was 66%. Three patients had progressive disease while on therapy. Kaplan-Meier estimates of progression-free survival are 80% at 1 year and 63% at 2 years. Major grade 3-4 toxicities included two patients with somnolence and one patient each with neuropathy, deep-vein thrombosis, hearing loss, weakness, sinus bradycardia, and edema. Thalidomide has significant activity in early-stage myeloma and has the potential to delay progression to symptomatic disease. This approach must be further tested in randomized trials.
Collapse
Affiliation(s)
- S V Rajkumar
- Division of Hematology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Porrata LF, Litzow MR, Tefferi A, Letendre L, Kumar S, Geyer SM, Markovic SN. Early lymphocyte recovery is a predictive factor for prolonged survival after autologous hematopoietic stem cell transplantation for acute myelogenous leukemia. Leukemia 2002; 16:1311-8. [PMID: 12094255 DOI: 10.1038/sj.leu.2402503] [Citation(s) in RCA: 99] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2001] [Accepted: 12/04/2001] [Indexed: 11/09/2022]
Abstract
Absolute lymphocyte count (ALC) recovery correlates with survival after autologous hematopoietic stem cell transplantation (AHSCT) for patients with multiple myeloma, non-Hodgkin's lymphoma, and metastatic breast cancer. The role of ALC recovery in relationship to clinical outcome after AHSCT in patients with acute myelogenous leukemia is unknown. We analyzed 45 patients who underwent AHSCT at Mayo Clinic, Rochester, Minnesota between 1990 and 2000. The ALC threshold was selected at 500 cells/microl on day 15 post-AHSCT based on our previous studies. Thirty-two females and 13 males were included in the study with a median age of 45 years (range 12-75). The median follow-up was 14 months with a maximum of 129 months. The median overall and leukemia-free survival were significantly better for the 23 patients with ALC at day 15 > or =500 cells/microl compared with 22 patients with ALC <500 cells/microl (not yet reached vs 10 months, P < 0.0009; 105 vs 9 months, P < 0.0008, respectively). In conclusion, ALC > or =500 cells/microl on day 15 post-AHSCT is associated with better survival in acute myelogenous leukemia and requires further studies.
Collapse
Affiliation(s)
- L F Porrata
- Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
| | | | | | | | | | | | | |
Collapse
|
18
|
Kay NE, Bone ND, Tschumper RC, Howell KH, Geyer SM, Dewald GW, Hanson CA, Jelinek DF. B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules. Leukemia 2002; 16:911-9. [PMID: 11986954 DOI: 10.1038/sj.leu.2402467] [Citation(s) in RCA: 106] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2001] [Accepted: 01/16/2002] [Indexed: 12/21/2022]
Abstract
Initial work has shown that clonal B cells from B-chronic lymphocytic leukemia (B-CLL) are able to synthesize pro-angiogenic molecules. In this study, our goal was to study the spectrum of angiogenic factors and receptors expressed in the CLL B cell. We used ELISA assays to determine the levels of basic fibroblast growth factors (bFGF), vascular endothelial growth factor (VEGF), endostatin, interferon-alpha (IFN-alpha) and thrombospondin-1 (TSP-1) secreted into culture medium by purified CLL B cells. These data demonstrated that CLL B cells spontaneously secrete a variety of pro- and anti-angiogenic factors, including bFGF (23.9 pg/ml +/- 7.9; mean +/- s.e.m.), VEGF (12.5 pg/ml +/- 2.3) and TSP-1 (1.9 ng/ml +/- 0.3). Out of these three factors, CLL B cells consistently secreted bFGF and TSP-1, while VEGF was expressed in approximately two-thirds of CLL patients. Of interest, hypoxic conditions dramatically upregulated VEGF expression at both the mRNA and protein levels. We also employed ribonuclease protection assays to assay CLL B cell expression of a variety of other angiogenesis-related molecules. These analyses revealed that CLL B cells consistently express mRNA for VEGF receptor 1 (VEGFR1), thrombin receptor, endoglin, and angiopoietin. Further analysis of VEGFR expression by RT-PCR revealed that CLL B cells expressed both VEGFR1 mRNA and VEGFR2 mRNA. In summary, these data collectively indicate that CLL B cells express both pro- and anti-angiogenic molecules and several vascular factor receptors. Because of the co-expression of angiogenic molecules and receptors for some of these molecules, these data suggest that the biology of the leukemic cells may also be directly impacted by angiogenic factors as a result of autocrine pathways of stimulation.
Collapse
MESH Headings
- Angiogenesis Inhibitors/biosynthesis
- Antigens, CD
- Autocrine Communication
- B-Lymphocytes/metabolism
- B-Lymphocytes/pathology
- Clone Cells/metabolism
- Clone Cells/pathology
- Cohort Studies
- Collagen/analysis
- Collagen/metabolism
- Endoglin
- Endostatins
- Endothelial Growth Factors/analysis
- Endothelial Growth Factors/metabolism
- Fibroblast Growth Factor 2/analysis
- Fibroblast Growth Factor 2/metabolism
- Germ-Line Mutation
- Growth Substances/biosynthesis
- Humans
- Interferon-alpha/analysis
- Interferon-alpha/metabolism
- Leukemia, Lymphocytic, Chronic, B-Cell/metabolism
- Leukemia, Lymphocytic, Chronic, B-Cell/pathology
- Lymphokines/analysis
- Lymphokines/metabolism
- Peptide Fragments/analysis
- Peptide Fragments/metabolism
- Proto-Oncogene Proteins/genetics
- RNA, Messenger/metabolism
- Receptor Protein-Tyrosine Kinases/genetics
- Receptors, Cell Surface
- Receptors, Growth Factor/biosynthesis
- Receptors, Growth Factor/genetics
- Receptors, Thrombin/genetics
- Receptors, Vascular Endothelial Growth Factor
- Thrombospondin 1/analysis
- Thrombospondin 1/metabolism
- Tumor Cells, Cultured
- Vascular Cell Adhesion Molecule-1/genetics
- Vascular Endothelial Growth Factor A
- Vascular Endothelial Growth Factor Receptor-1
- Vascular Endothelial Growth Factors
Collapse
Affiliation(s)
- N E Kay
- Department of Medicine, Division of Hematology, Mayo Graduate and Medical Schools, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
| | | | | | | | | | | | | | | |
Collapse
|
19
|
Jelinek DF, Tschumper RC, Geyer SM, Bone ND, Dewald GW, Hanson CA, Stenson MJ, Witzig TE, Tefferi A, Kay NE. Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia. Br J Haematol 2001; 115:854-61. [PMID: 11843819 DOI: 10.1046/j.1365-2141.2001.03149.x] [Citation(s) in RCA: 165] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Recent reports suggest that the expression of germline (GL) Ig variable region heavy-chain genes (VH) is a negative prognostic factor for B-cell chronic lymphocytic leukaemia (B-CLL) patients and that CLL B-cell CD38 expression may be a surrogate marker of Ig VH gene status. Currently, however, the usefulness of this surrogate marker is controversial. Therefore, our goal was to study the ability of CD38 to act as a surrogate marker for Ig VH somatic mutation (SM), and to identify differences in overall survival (OS), progression-free survival (PFS) and response in B-CLL patients based on these two markers. We first assessed the relationship between CD38 expression and Ig VH status on 131 B-CLL patients, including 66 patients enrolled in three North Central Cancer Treatment Group Trials. Although the mean percentages of CD38+ clonal B cells were significantly higher for patients classified as GL versus SM, CD38 was not a reliable marker for clonal B-cell SM. Overall, GL patients exhibited significantly shorter OS and PFS times than SM patients. Despite the inability of clonal B-cell CD38 expression to predict Ig VH mutation status, patients with < or =30% CD38+ cells did have shorter PFS and OS times than did CLL patients with < 30% CD38+ cells. Thus, the relationship between CD38 expression and Ig VH mutation status in B-CLL is not straightforward. Nevertheless, analysis in a co-operative group clinical trial setting suggests that both B-cell markers alone or in combination may have clinical usefulness. These data strongly encourage the study of these biological markers as they relate to disease heterogeneity in B-CLL.
Collapse
MESH Headings
- ADP-ribosyl Cyclase
- ADP-ribosyl Cyclase 1
- Antigens, CD
- Antigens, Differentiation/analysis
- B-Lymphocytes/immunology
- Biomarkers/analysis
- Disease Progression
- Disease-Free Survival
- Genes, Immunoglobulin
- Genetic Markers
- Humans
- Leukemia, Lymphocytic, Chronic, B-Cell/genetics
- Leukemia, Lymphocytic, Chronic, B-Cell/immunology
- Membrane Glycoproteins
- NAD+ Nucleosidase/analysis
- Proportional Hazards Models
- Risk
- Somatic Hypermutation, Immunoglobulin
- Statistics, Nonparametric
- Survival Rate
Collapse
Affiliation(s)
- D F Jelinek
- Department of Immunology, Mayo Graduate and Medical Schools, Mayo Clinic, 200 1st Street SW, Rochester, MN 55905, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Porrata LF, Gertz MA, Inwards DJ, Litzow MR, Lacy MQ, Tefferi A, Gastineau DA, Dispenzieri A, Ansell SM, Micallef IN, Geyer SM, Markovic SN. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood 2001; 98:579-85. [PMID: 11468153 DOI: 10.1182/blood.v98.3.579] [Citation(s) in RCA: 229] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Autologous stem cell transplantation (ASCT) improves survival in patients with previously untreated multiple myeloma (MM) and relapsed, chemotherapy-sensitive, aggressive non-Hodgkin lymphoma (NHL). Lower relapse rates seen in allogeneic stem cell transplantation have been related to early absolute lymphocyte count (ALC) recovery as a manifestation of early graft-verus-tumor effect. In ASCT, the relation between ALC recovery and clinical outcomes in MM and NHL was not previously described. This is a retrospective study of patients with MM and NHL who underwent ASCT at the Mayo Clinic between 1987 and 1999. The ALC threshold was determined at 500 cells/microL on day 15 after ASCT. The study identified 126 patients with MM and 104 patients with NHL. The median overall survival (OS) and progression-free survival (PFS) times for patients with MM were significantly longer in patients with an ALC of 500 cells/microL or more than patients with an ALC of fewer than 500 cells/microL (33 vs 12 months, P <.0001; 16 vs 8 months, P <.0003, respectively). For patients with NHL, the median OS and PFS times were significantly longer in patients with an ALC of 500 cells/microL or more versus those with fewer than 500 cells/microL (not reached vs 6 months, P <.0001; not reached vs 4 months, P <.0001, respectively). Multivariate analysis demonstrated day 15 ALC to be an independent prognostic indicator for OS and PFS rates for both groups of patients. In conclusion, ALC is correlated with clinical outcome and requires further study. (Blood. 2001;98:579-585)
Collapse
Affiliation(s)
- L F Porrata
- Division of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Tefferi A, Li CY, Reeder CB, Geyer SM, Allmer C, Levitt R, Michalak JC, Addo F, Krook JE, Witzig TE, Schaefer PL, Mailliard JA. A phase II study of sequential combination chemotherapy with cyclophosphamide, prednisone, and 2-chlorodeoxyadenosine in previously untreated patients with chronic lymphocytic leukemia. Leukemia 2001; 15:1171-5. [PMID: 11480558 DOI: 10.1038/sj.leu.2402172] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
In an earlier study of previously untreated patients with chronic lymphocytic leukemia (CLL), we used a concomitant combination of chlorambucil and 2-chlorodeoxyadenosine and reported overall (OR) and complete (CR) remission rates of 80% and 20%, respectively. After a median follow-up of 5 years, more than 80% of the responders have had a relapse. In the current phase II study of 27 previously untreated patients with CLL, we used a sequential combination of six cycles of intravenous cyclophosphamide (1 g/m2) plus oral prednisone (100 mg/m2 per day for 5 days) followed by two to six cycles of 2-chlorodeoxyadenosine (5 mg/m2 per day for 5 days). The OR and CR rates were 96% and 33%, respectively. After a median follow-up of 29 months, 35% of the responders have had a relapse. Progression-free survival was significantly better in CR patients than in those with partial remission. However, minimal residual disease was phenotypically detected in four of the nine CR patients. Despite the fact that the current OR and CR rates are superior to those seen in a historical cohort treated with a concomitant schedule, a longer follow-up period is needed to assess the durability of these remissions, and a controlled trial is necessary to estimate the impact on overall survival and toxicity.
Collapse
Affiliation(s)
- A Tefferi
- Mayo Clinic, Rochester, MN 55905, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Tustin RC, Geyer SM. Transmission of ovine jaagsiekte using neoplastic cells grown in tissue culture. J S Afr Vet Med Assoc 1971; 42:181-2. [PMID: 5170646] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
|